Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study

被引：0
|
作者：
Yoichiro Yoshida
Takeshi Yamada
Hirohiko Kamiyama
Chihiro Kosugi
Keiichiro Ishibashi
Hiroshi Yoshida
Hideyuki Ishida
Satoru Yamaguchi
Hidekazu Kuramochi
Atsuko Fukazawa
Hiromichi Sonoda
Kazuhiko Yoshimatsu
Akihisa Matsuda
Suguru Hasegawa
Kazuhiro Sakamoto
Toshiaki Otsuka
Keiji Koda
机构：
[1] Fukuoka University,Department of Gastroenterological Surgery, Faculty of Medicine
[2] Fukuoka University School of Medicine,Department of Gastrointestinal and Hepato
[3] Nippon Medical School,Biliary
[4] Juntendo University,Pancreatic Surgery
[5] Teikyo University Chiba Medical Center,Department of Coloproctological Surgery, Faculty of Medicine
[6] Saitama Medical University,Department of Surgery
[7] Dokkyo Medical University,Department of Digestive Tract and General Surgery, Saitama Medical Center
[8] Tokyo Women’s Medical University Yachiyo Medical Center,Department of Surgical Oncology
[9] Iwata City Hospital,Department of Chemotherapy
[10] Shiga University of Medical Science,Department of Gastroenterological Surgery
[11] Saiseikai Kurihashi Hospital,Department of Surgery
[12] Nippon Medical School Chiba Hokuso Hospital,Department of Surgery
[13] Nippon Medical School,Department of Surgery
来源：
International Journal of Clinical Oncology | 2021年 / 26卷
关键词：
Bevacizumab; Chemotherapy; Colorectal cancer; TAS-102; Neutropenia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：111 / 117
页数：6
相关论文
共 50 条
  • [1] Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
    Yoshida, Yoichiro
    Yamada, Takeshi
    Kamiyama, Hirohiko
    Kosugi, Chihiro
    Ishibashi, Keiichiro
    Yoshida, Hiroshi
    Ishida, Hideyuki
    Yamaguchi, Satoru
    Kuramochi, Hidekazu
    Fukazawa, Atsuko
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Matsuda, Akihisa
    Hasegawa, Suguru
    Sakamoto, Kazuhiro
    Otsuka, Toshiaki
    Koda, Keiji
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 111 - 117
  • [2] The combination of TAS-102 and bevacizumab as the third-line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study).
    Kosugi, Chihiro
    Kamiyama, Hirohiko
    Yoshida, Yoichiro
    Yoshida, Hiroshi
    Ishibashi, Keiichiro
    Ihara, Keisuke
    Takahashi, Makoto
    Kuramochi, Hidekazu
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Fukazawa, Atsuko
    Matsuda, Akihisa
    Yamaguchi, Satoru
    Ishida, Hideyuki
    Hasegawa, Suguru
    Yamada, Takeshi
    Narushima, Kazuo
    Shuto, Kiyohiko
    Sakamoto, Kazuhiro
    Koda, Keiji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [3] The combination of TAS-102 and bevacizumab as the third line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study)
    Kamiyama, H.
    Yoshida, Y.
    Yoshida, H.
    Kosugi, C.
    Ishibashi, K.
    Ihara, K.
    Takahashi, M.
    Kuramochi, H.
    Fukazawa, A.
    Sonoda, H.
    Yoshimatsu, K.
    Matsuda, A.
    Yamaguchi, S.
    Ishida, H.
    Hasegawa, S.
    Yamada, T.
    Sakamoto, K.
    Koda, K.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 157 - 157
  • [4] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Mouri, Takashi
    Ishida, Kota
    Matsumoto, Nori
    Akiba, Tadashi
    Yanaga, Katsuhiko
    [J]. ANTICANCER RESEARCH, 2018, 38 (04) : 2419 - 2422
  • [5] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Yanaga, Katsuhiko
    [J]. CANCER SCIENCE, 2018, 109 : 601 - 601
  • [6] Biweekly TAS-102 and bevacizumab as a third-line chemotherapy for metastatic colorectal cancer: A phase II multicenter clinical trial (TAS-CC4 study)
    Yoshida, Y.
    Yamada, T.
    Matsuoka, H.
    Hirata, K.
    Kuramochi, H.
    Kosugi, C.
    Takahashi, M.
    Fukazawa, A.
    Sonoda, H.
    Matsuda, A.
    Watanabe, T.
    Koizumi, M.
    Aisu, N.
    Hasegawa, S.
    Yoshida, H.
    Sakamoto, K.
    Ishida, H.
    Koda, K.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 235 - 235
  • [7] The pretreatment lymphocyte-to-monocyte ratio (LMR) to predict treatment efficacy and prognosis in metastatic colorectal cancer treated with the combination of TAS-102 and bevacizumab (TAS-CC3 Study)
    Matsuda, Akihisa
    Yoshida, Yoichiro
    Kamiyama, Hirohiko
    Kosugi, Chihiro
    Yoshida, Hiroshi
    Ishibashi, Keiichiro
    Ihara, Keisuke
    Takahashi, Makoto
    Kuramochi, Hidekazu
    Fukazawa, Atsuko
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Yamaguchi, Satoru
    Ishida, Hideyuki
    Hasegawa, Suguru
    Yamada, Takeshi
    Sakamoto, Kazuhiro
    Koda, Keiji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [8] TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
    Liu, Cheng-Jiang
    Hu, Ting
    Shao, Ping
    Chu, Wu-Yang
    Cao, Yu
    Zhang, Feng
    [J]. GASTROENTEROLOGY RESEARCH AND PRACTICE, 2021, 2021
  • [9] TAS-102 plus bevacizumab in metastatic colorectal cancer
    Colloca, Giuseppe A.
    Venturino, Antonella
    [J]. LANCET ONCOLOGY, 2020, 21 (05): : E226 - E226
  • [10] Fruquintinib in combination with sintilimab or TAS-102 as third-line or above treatment in patients with metastatic colorectal cancer: a real-world study
    Li, Luchun
    Wang, Ting
    Wu, Zhijuan
    Li, Yan
    Ma, Huiwen
    Wang, Lulu
    Lei, Shuangyi
    Chen, Wen
    [J]. TRANSLATIONAL CANCER RESEARCH, 2023, 12 (11) : 3034 - 3044
12345